Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects

Severe Hepatic Impairment Clinical Trial

Official title:
Open Label Study to Evaluate the Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy Subjects and Subjects With Severe Hepatic Impairment

Status Terminated

Clinical Trial Summary

The primary objective of this study is to characterize the steady state plasma

Clinical Trial Description

The primary objective of this study is to characterize the steady state plasma PK of rifaximin (550 mg BID) in subjects with severe hepatic impairment (MELD 19 to 25 and MELD >25), as well as healthy subjects with normal hepatic function. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03818672
Study type	Interventional
Source	Bausch Health Americas, Inc.
Contact
Status	Terminated
Phase	Phase 4
Start date	January 29, 2019
Completion date	February 2, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03664544` - PK Study in Subjects With Severe Hepatic Impairment	Phase 1
Completed	`NCT05116826` - Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients	Phase 1
Completed	`NCT05199610` - An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143	Phase 1
Completed	`NCT02170220` - Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment	Phase 1
Completed	`NCT02138162` - A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men	Phase 1
Completed	`NCT03865446` - Evaluate Severe Hepatic Impairment on Dacomitinib PK	Phase 1
Recruiting	`NCT05224609` - A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction	Phase 1